Provectus Biopharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $251.3K | $307.4K | $76.6K | $21.6K | $683.0K | $97.2K | $590.7K | $51.0K |
| Accounts Receivable | — | — | $476 | $394 | $5.1K | $3.9K | $55.1K | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $567.9K | $976.8K | $1.4M | $1.9M | $3.4M | $423.7K | $996.0K | $1.0M |
| Property, Plant & Equipment | $3.0K | $4.9K | $12.0K | $20.9K | $31.8K | $44.7K | $58.4K | $72.5K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | $228.1K | $899.2K |
| Total Assets | $697.5K | $1.0M | $1.4M | $2.0M | $3.5M | $589.2K | $1.5M | $2.0M |
| Liabilities | ||||||||
| Accounts Payable | $716.2K | $1.1M | $1.7M | $2.1M | $1.3M | $956.9K | $1.1M | $3.3M |
| Total Current Liabilities | $6.9M | $7.0M | $9.0M | $8.2M | $7.7M | $30.7M | $3.0M | $4.1M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $7.0M | $7.0M | $9.0M | $8.3M | $7.7M | $30.8M | $25.5M | $19.4M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-262.9M | $-257.4M | $-252.7M | $-249.6M | $-246.0M | $-240.5M | $-233.8M | $-226.9M |
| Total Stockholders' Equity | $-6.3M | $-6.0M | $-7.6M | $-6.2M | $-4.2M | $-30.2M | $-24.1M | $-17.4M |